Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

BACKGROUND: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clinicoecon Outcomes Res
Main Authors: Gibson, EJ, Begum, N, Koblbauer, I, Dranitsaris, G, Liew, D, McEwan, P, Tahami Monfared, AA, Yuan, Y, Juarez-Garcia, A, Tyas, D, Lees, M
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848668/
https://ncbi.nlm.nih.gov/pubmed/29563820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S144208
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares